HealthTree Podcast for Multiple Myeloma

HealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

https://www.blogtalkradio.com/myelomacrowdradio

subscribe
share






episode 10: Myeloma Crowd Radio: Maria Chaudhry, MD, Ohio State University


At last year's ASH meeting, there was excitement around a new antibody drug conjugate targeting a protein called BCMA from Glaxo Smith Klein. Results from their Phase I study showed that patients who had relapsed immunomodulators (like Revlimid), proteasome inhibitors (like Velcade) and even monoclonal antibodies (like daratumumab), responded when taking this drug alone (60% response rate). Learn more from Dr. Maria Chaudhry of Ohio State University about current studies using this new drug and when patients could consider it in the course of their treatment.  Thanks to our episode sponsor, Celgene. 


fyyd: Podcast Search Engine
share








 September 13, 2018  1h0m